Immunoglobulin G dose-exposure-efficacy response in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

What was studied

This analysis looked at doses of immune globulin in CIDP. CIDP is a rare nerve disease. Both IVIG and fSCIG are used for maintenance. Data on dose, exposure and outcome were sparse. The team pooled data from phase 3 studies in CIDP and in multifocal motor neuropathy. They built a model linking blood IgG levels to rising INCAT disability scores.

What they found

The team then simulated several dosing plans. Plans used 6 months of IVIG, or 3 months of IVIG then fSCIG. Doses ranged from 0.4 to 2.0 g/kg, every 2 to 4 weeks. Higher, more frequent doses went with a lower chance of rising INCAT scores. That means a lower chance of relapse. The chance tended to be higher late in the dosing gap for less frequent dosing.

What it means for patients

The authors said higher, more frequent dosing may give a steadier effect in CIDP. They said links between dose, exposure and outcome were sparse before.

Why it is not certain yet

This was a model-based simulation, not a new trial. Data came from studies in CIDP and in multifocal motor neuropathy. The results are predictions, not measured outcomes. Data on dose and exposure were sparse because the condition is rare.

Source

Immunoglobulin G dose-exposure-efficacy response in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

We restate facts from the source record in our own words. The original wording belongs to its publisher.